Center Educational Forum attendees illustrated a theme related to adjuvant therapy delay. Providers were surprised to learn that as many as 10% of patients were not recorded as receiving adjuvant endocrine therapy. Performance on this measure did not
Search Results
Tara M. Breslin, Marcy Waldinger, and Samuel M. Silver
Rosalyn A. Juergens and Julie R. Brahmer
. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer . Eastern Cooperative Oncology Group . N Engl J Med 2000 ; 343 : 1217 – 1222 . 20. Mineo TC Ambrogi V
Al B. Benson III, Alan P. Venook, Mahmoud M. Al-Hawary, Lynette Cederquist, Yi-Jen Chen, Kristen K. Ciombor, Stacey Cohen, Harry S. Cooper, Dustin Deming, Paul F. Engstrom, Ignacio Garrido-Laguna, Jean L. Grem, Axel Grothey, Howard S. Hochster, Sarah Hoffe, Steven Hunt, Ahmed Kamel, Natalie Kirilcuk, Smitha Krishnamurthi, Wells A. Messersmith, Jeffrey Meyerhardt, Eric D. Miller, Mary F. Mulcahy, James D. Murphy, Steven Nurkin, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky-Himelfarb, Christopher G. Willett, Evan Wuthrick, Kristina M. Gregory, and Deborah A. Freedman-Cass
, adjuvant chemotherapy. 10 Population and institutional studies have shown that adjuvant therapy may confer a survival advantage in some patients with resected colon cancer (eg, those with stage III or high-risk stage II disease). 11 – 14 Furthermore
NCCN Guidelines Insights: Pancreatic Adenocarcinoma, Version 1.2019
Featured Updates to the NCCN Guidelines
Margaret A. Tempero, Mokenge P. Malafa, E. Gabriela Chiorean, Brian Czito, Courtney Scaife, Amol K. Narang, Christos Fountzilas, Brian M. Wolpin, Mahmoud Al-Hawary, Horacio Asbun, Stephen W. Behrman, Al B. Benson III, Ellen Binder, Dana B. Cardin, Charles Cha, Vincent Chung, Mary Dillhoff, Efrat Dotan, Cristina R. Ferrone, George Fisher, Jeffrey Hardacre, William G. Hawkins, Andrew H. Ko, Noelle LoConte, Andrew M. Lowy, Cassadie Moravek, Eric K. Nakakura, Eileen M. O’Reilly, Jorge Obando, Sushanth Reddy, Sarah Thayer, Robert A. Wolff, Jennifer L. Burns, and Griselda Zuccarino-Catania
only approximately half of patients with potentially curative resections receive adjuvant therapy due to issues associated with postoperative complications, recovery, and performance status. 9 Median survival for patients with resected tumors under
James Sun, Brittany J. Mathias, Christine Laronga, Weihong Sun, Jun-Min Zhou, William J. Fulp, John V. Kiluk, and M. Catherine Lee
without records of adjuvant therapy were excluded. Patients were identified from a prospectively maintained breast cancer database at an NCI-designated Comprehensive Cancer Center. Clinicopathologic variables, including demographic information, pathology
Richard B. Hostetter, Min Yan, Houman Vaghefi, Kenneth Pennington, and Gary Cornette
higher total doses (60–66 Gy in 30–33 fractions). The advantage of adjuvant therapy is that the final pathology is clearly established. 3 Figure 6 Spindle tumor cells in bundle and fascicles (hematoxylin-eosin stain, original magnification x100
Margaret A. Tempero
pancreatic cancer, 80% of patients are diagnosed with advanced unresectable disease; 80% experience relapse after resection and adjuvant therapy; and median overall survival (OS) of patients with untreated metastatic disease is only 3 months. The “cure rate
Eric Jonasch
in Oncology (NCCN Guidelines) for Kidney Cancer. Adjuvant Therapy Three trials have been conducted in the adjuvant setting, 2 of which (ASSURE and PROTECT) showed negative results for adjuvant sunitinib, sorafenib, and pazopanib. A third trial
Paul F. Engstrom
2002, the NCCN panel advocated 5-fluorouracil (5-FU)/leucovorin adjuvant therapy for stage III or node-positive disease and 5-FU leucovorin with or without irinotecan (IFL) as first-line therapy for metastatic disease. Second-line therapies for
Prajnan Das, Norio Fukami, and Jaffer A. Ajani
. 29. Gunderson LL Sosin H . Adenocarcinoma of the stomach: areas of failure in a re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy . Int J Radiat Oncol Biol Phys 1982 ; 8 : 1
